Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Alumis Inc. Market Cap
The Alumis Inc. (ALMS) share price is expected to increase by 212.37% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered ALMS. Price targets range from $29 at the low end to $36 at the high end. The current analyst consensus for ALMS is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
Alumis Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Alumis Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of ALMS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Eric Schmidt Cantor Fitzgerald | Overweight | Reiterates | Aug 19, 2024 | |
| Terence Flynn Morgan Stanley | Overweight | $36 | Initiates | Jul 23, 2024 |
| Yatin Suneja Guggenheim | Buy | $32 | Initiates | Jul 23, 2024 |
| Eric Schmidt Cantor Fitzgerald | Overweight | Initiates | Jul 23, 2024 | |
| Thomas Smith Leerink Partners | Outperform | $29 | Initiates | Jul 23, 2024 |
When did it IPO
N/A
Staff Count
128
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Martin Babler Ph.D.
Market Cap
$559.8M
In 2023, ALMS generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ALMS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 04 Oct 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Alumis is in advanced testing for a drug with potential for multiple indications. Shares are currently 30% below the IPO price, backed by major healthcare hedge funds.
Why It Matters - Alumis's advanced drug testing and prominent hedge fund backing signal potential for significant growth, especially at a discounted price, attracting interest from investors seeking high returns.
Fri, 27 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Alumis Inc. reported positive 28-week data for ESK-001, with good tolerance and efficacy in treating moderate-to-severe plaque psoriasis. Full 52-week data expected in 1H 2025; Phase 3 trials ongoing.
Why It Matters - Positive data for ESK-001 suggests strong efficacy and tolerability, enhancing Alumis Inc.'s prospects in the psoriasis market, potentially driving stock value and investor interest.
Mon, 16 Sep 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Alumis's ESK-001, a phase 3 TYK2 inhibitor for psoriasis and SLE, shows better efficacy and safety than current treatments. However, risks remain due to market competition and recent IPO status.
Why It Matters - Alumis' ESK-001 shows promising efficacy and safety, potentially disrupting the TYK2 inhibitor market. However, competition and its recent IPO status introduce significant investment risks.
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Alumis Inc. (Nasdaq: ALMS) will participate in several investor conferences in September 2024, including Morgan Stanley, Wells Fargo, and Baird, focusing on its developments in oral therapies for immune-mediated diseases.
Why It Matters - Alumis Inc.'s participation in major investor conferences highlights its engagement with the investment community, signaling potential growth and interest in its innovative therapies for immune-mediated diseases.
Tue, 13 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Alumis Inc. has initiated patient dosing in a Phase 3 trial for ESK-001 and a Phase 1 trial for A-005, and completed an IPO raising $250M. Financial results for Q2 2024 were also reported.
Why It Matters - Alumis Inc.'s advancements in clinical trials and successful fundraising enhance its growth potential, signaling strong investor confidence and opportunities in the biopharmaceutical sector.
Mon, 29 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Alumis Inc. has begun patient dosing in its ONWARD Phase 3 clinical program, with topline data expected in 2026 to support a U.S. regulatory submission based on positive Phase 2 results.
Why It Matters - Alumis Inc.'s Phase 3 trial initiation and positive Phase 2 results boost investor confidence in potential FDA approval, impacting stock performance and future revenue projections.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
